올리고뉴클레오티드 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Oligonucleotides Market - Scope of Report

TMR's report on the global oligonucleotides market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global oligonucleotides market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oligonucleotides market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the oligonucleotides market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oligonucleotides market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oligonucleotides market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oligonucleotides market.

The report delves into the competitive landscape of the global oligonucleotides market. Key players operating in the global oligonucleotides market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oligonucleotides market profiled in this report.

Key Questions Answered in Global oligonucleotides Market Report:

• What is the sales/revenue generated by oligonucleotides across all regions during the forecast period?
• What are the opportunities in the global oligonucleotides market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Oligonucleotides Market - Research Objectives and Research Approach

The comprehensive report on the global oligonucleotides market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oligonucleotides market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oligonucleotides market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Oligonucleotides Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segmentation Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Oligonucleotides Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. No. of Oligonucleotides being developed in world by Key Regions
• 5.2. List of top Oligonucleotides products
• 5.3. Pricing Analysis
• 5.4. Go-to-Market Strategy
• 5.5. Key Purchase Metrics for End-users
• 5.6. PESTEL Analysis
• 5.7. Key Industry Events
• 5.8. Porter's Five Forces Analysis
• 5.9. Regulatory Scenario by Key Countries/Regions
• 5.10. Product/Brand Analysis
• 5.11. Distributors Landscape
• 5.12. Technological Advancements
• 5.13. Fund Raise/Investment Scenario
• 5.14. Recommendations and Analyst View for the Market

6. Global Oligonucleotides Market Analysis and Forecasts, By Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Type, 2020-2034
  • 6.3.1. Antisense Oligonucleotides
  • 6.3.2. DNA
  • 6.3.3. siRNA
  • 6.3.4. Others (CpG Oligonucleotides)
• 6.4. Market Attractiveness By Type

7. Global Oligonucleotides Market Analysis and Forecasts, By Application

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Application, 2020-2034
  • 7.3.1. Molecular Biology
  • 7.3.2. Gene Therapy
  • 7.3.3. Drug Development
  • 7.3.4. Diagnostics
  • 7.3.5. Others (Nanotechnology, Research studies etc.)
• 7.4. Market Attractiveness By Application

8. Global Oligonucleotides Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020-2034
  • 8.3.1. Hospitals
  • 8.3.2. Pharma & Biopharma Companies
  • 8.3.3. Diagnostic Laboratories
  • 8.3.4. Biotechnology Companies
  • 8.3.5. CROs and CMOs
  • 8.3.6. Others (Academic Research Institutes, etc.)
• 8.4. Market Attractiveness By End-user

9. Global Oligonucleotides Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Oligonucleotides Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Type, 2020-2034
  • 10.2.1. Antisense Oligonucleotides
  • 10.2.2. DNA
  • 10.2.3. siRNA
  • 10.2.4. Others (CpG Oligonucleotides)
• 10.3. Market Value Forecast By Application, 2020-2034
  • 10.3.1. Molecular Biology
  • 10.3.2. Gene Therapy
  • 10.3.3. Drug Development
  • 10.3.4. Diagnostics
  • 10.3.5. Others (Nanotechnology, Research studies etc.)
• 10.4. Market Value Forecast By End-user, 2020-2034
  • 10.4.1. Hospitals
  • 10.4.2. Pharma & Biopharma Companies
  • 10.4.3. Diagnostic Laboratories
  • 10.4.4. Biotechnology Companies
  • 10.4.5. CROs and CMOs
  • 10.4.6. Others (Academic Research Institutes, etc.)
• 10.5. Market Value Forecast By Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Type
  • 10.6.2. By Application
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Oligonucleotides Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Type, 2020-2034
  • 11.2.1. Antisense Oligonucleotides
  • 11.2.2. DNA
  • 11.2.3. siRNA
  • 11.2.4. Others (CpG Oligonucleotides)
• 11.3. Market Value Forecast By Application, 2020-2034
  • 11.3.1. Molecular Biology
  • 11.3.2. Gene Therapy
  • 11.3.3. Drug Development
  • 11.3.4. Diagnostics
  • 11.3.5. Others (Nanotechnology, Research studies etc.)
• 11.4. Market Value Forecast By End-user, 2020-2034
  • 11.4.1. Hospitals
  • 11.4.2. Pharma & Biopharma Companies
  • 11.4.3. Diagnostic Laboratories
  • 11.4.4. Biotechnology Companies
  • 11.4.5. CROs and CMOs
  • 11.4.6. Others (Academic Research Institutes, etc.)
• 11.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 11.5.1. Germany
  • 11.5.2. UK
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Type
  • 11.6.2. By Application
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Oligonucleotides Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Type, 2020-2034
  • 12.2.1. Antisense Oligonucleotides
  • 12.2.2. DNA
  • 12.2.3. siRNA
  • 12.2.4. Others (CpG Oligonucleotides)
• 12.3. Market Value Forecast By Application, 2020-2034
  • 12.3.1. Molecular Biology
  • 12.3.2. Gene Therapy
  • 12.3.3. Drug Development
  • 12.3.4. Diagnostics
  • 12.3.5. Others (Nanotechnology, Research studies etc.)
• 12.4. Market Value Forecast By End-user, 2020-2034
  • 12.4.1. Hospitals
  • 12.4.2. Pharma & Biopharma Companies
  • 12.4.3. Diagnostic Laboratories
  • 12.4.4. Biotechnology Companies
  • 12.4.5. CROs and CMOs
  • 12.4.6. Others (Academic Research Institutes, etc.)
• 12.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Type
  • 12.6.2. By Application
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Oligonucleotides Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Type, 2020-2034
  • 13.2.1. Antisense Oligonucleotides
  • 13.2.2. DNA
  • 13.2.3. siRNA
  • 13.2.4. Others (CpG Oligonucleotides)
• 13.3. Market Value Forecast By Application, 2020-2034
  • 13.3.1. Molecular Biology
  • 13.3.2. Gene Therapy
  • 13.3.3. Drug Development
  • 13.3.4. Diagnostics
  • 13.3.5. Others (Nanotechnology, Research studies etc.)
• 13.4. Market Value Forecast By End-user, 2020-2034
  • 13.4.1. Hospitals
  • 13.4.2. Pharma & Biopharma Companies
  • 13.4.3. Diagnostic Laboratories
  • 13.4.4. Biotechnology Companies
  • 13.4.5. CROs and CMOs
  • 13.4.6. Others (Academic Research Institutes, etc.)
• 13.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of LATAM
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Type
  • 13.6.2. By Application
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Oligonucleotides Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Type, 2020-2034
  • 14.2.1. Antisense Oligonucleotides
  • 14.2.2. DNA
  • 14.2.3. siRNA
  • 14.2.4. Others (CpG Oligonucleotides)
• 14.3. Market Value Forecast By Application, 2020-2034
  • 14.3.1. Molecular Biology
  • 14.3.2. Gene Therapy
  • 14.3.3. Drug Development
  • 14.3.4. Diagnostics
  • 14.3.5. Others (Nanotechnology, Research studies etc.)
• 14.4. Market Value Forecast By End-user, 2020-2034
  • 14.4.1. Hospitals
  • 14.4.2. Pharma & Biopharma Companies
  • 14.4.3. Diagnostic Laboratories
  • 14.4.4. Biotechnology Companies
  • 14.4.5. CROs and CMOs
  • 14.4.6. Others (Academic Research Institutes, etc.)
• 14.5. Market Value Forecast By Country/Sub-region, 2020-2034
  • 14.5.1. South Africa
  • 14.5.2. GCC Countries
  • 14.5.3. Rest of MEA
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Type
  • 14.6.2. By Application
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Agilent Technologies
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Ajinomoto Bio-Pharma Services
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. CordenPharma
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Creative Biolabs
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Ella Biotech
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Eurofins Genomics
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Future synthesis
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Integrated DNA Technologies
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Kaneka Eurogentec
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Thermo Fisher Scientific Inc.
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis
    • 15.3.10.5. Strategic Overview
  • 15.3.11. Merck
    • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.11.2. Product Portfolio
    • 15.3.11.3. Financial Overview
    • 15.3.11.4. SWOT Analysis
    • 15.3.11.5. Strategic Overview
  • 15.3.12. Microsynth
    • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.12.2. Product Portfolio
    • 15.3.12.3. Financial Overview
    • 15.3.12.4. SWOT Analysis
    • 15.3.12.5. Strategic Overview
  • 15.3.13. Nitto Avecia
    • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.13.2. Product Portfolio
    • 15.3.13.3. Financial Overview
    • 15.3.13.4. SWOT Analysis
    • 15.3.13.5. Strategic Overview